loading
Atea Pharmaceuticals Inc stock is traded at $2.98, with a volume of 551.04K. It is down -0.33% in the last 24 hours and up +3.47% over the past month. Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$2.99
Open:
$3.02
24h Volume:
551.04K
Relative Volume:
1.61
Market Cap:
$247.32M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.4396
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
+3.11%
1M Performance:
+3.47%
6M Performance:
-9.42%
1Y Performance:
-22.19%
1-Day Range:
Value
$2.9501
$3.08
1-Week Range:
Value
$2.825
$3.08
52-Week Range:
Value
$2.60
$4.145

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name
Name
Atea Pharmaceuticals Inc
Name
Phone
857-204-8109
Name
Address
225 FRANKLIN STREET, BOSTON
Name
Employee
56
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AVIR's Discussions on Twitter

Compare AVIR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AVIR
Atea Pharmaceuticals Inc
2.98 247.32M 351.37M -174.01M -126.94M -2.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-13-24 Upgrade Morgan Stanley Underweight → Equal-Weight
Aug-10-23 Downgrade JP Morgan Neutral → Underweight
Jan-06-22 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-18-21 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-20-21 Downgrade JP Morgan Overweight → Neutral
Oct-05-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-25-20 Initiated Evercore ISI Outperform
Nov-24-20 Initiated JP Morgan Overweight
Nov-24-20 Initiated Morgan Stanley Overweight
Nov-24-20 Initiated William Blair Outperform
View All

Atea Pharmaceuticals Inc Stock (AVIR) Latest News

pulisher
May 01, 2025

A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times

May 01, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX

Apr 25, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News

Apr 22, 2025
pulisher
Apr 22, 2025

Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace

Apr 22, 2025
pulisher
Apr 18, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharma Doubles Down: $25M Share Buyback Plan Unveiled as Strategic Review Accelerates - Stock Titan

Apr 17, 2025
pulisher
Apr 13, 2025

Morgan Stanley Issues Pessimistic Forecast for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price - Defense World

Apr 13, 2025
pulisher
Apr 11, 2025

Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR - Benzinga

Apr 11, 2025
pulisher
Apr 10, 2025

Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study - MSN

Apr 10, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan

Apr 09, 2025
pulisher
Apr 05, 2025

HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 05, 2025
pulisher
Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com

Apr 01, 2025
pulisher
Mar 31, 2025

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times

Mar 31, 2025
pulisher
Mar 29, 2025

Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener

Mar 26, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 24, 2025
pulisher
Mar 22, 2025

Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire

Mar 22, 2025
pulisher
Mar 21, 2025

Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener

Mar 21, 2025

Atea Pharmaceuticals Inc Stock (AVIR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Cap:     |  Volume (24h):